PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
37.34%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
47.13%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
50.90%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
52.86%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
7.67%
Share reduction more than 1.5x AVXL's 33.28%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
12.32%
Diluted share reduction more than 1.5x AVXL's 33.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
33.57%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
33.08%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Negative 10Y OCF/share CAGR while AVXL stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-7404.36%
Negative 5Y OCF/share CAGR while AVXL is at 63.94%. Joel Greenblatt would question the firm’s operational model or cost structure.
-3986.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-11268.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-11424.82%
Negative 5Y net income/share CAGR while AVXL is 40.23%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
97.34%
3Y net income/share CAGR 1.25-1.5x AVXL's 65.35%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
5Y equity/share CAGR above 1.5x AVXL's 126.75%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
547.30%
3Y equity/share CAGR above 1.5x AVXL's 218.65%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Negative asset growth while AVXL invests at 26.37%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.66%
We have a declining book value while AVXL shows 12.08%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-26.31%
Our R&D shrinks while AVXL invests at 96.36%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-49.44%
We cut SG&A while AVXL invests at 58.14%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.